Tel. : 514.945.9795
Mail : firstname.lastname@example.org
Active in the health economics field since the late 80s, with more than 25 years of health economics consulting experience in the North American and European pharmaceutical & healthcare technologies industries, Julie has established a reputation for excellence in the planning and implementation of pharmacoeconomics and outcome research studies that meet and exceed client expectations.
In her work on more than 250 health economic projects, Julie has maintained a focus on economic piggyback studies, economic risk management trials, price justification, market identification and justification and disease management. Julie has substantially contributed to Quebec and Canada’s growing R&D-oriented healthcare industries by providing her unique expertise to key organizations.
Julie has acted as advisor in health economic studies for the Quebec Hospital Association (AHQ) and filled the role of chairperson to the 1st AHQ pharmacoeconomics workshop in 1993. Julie has also been a speaker at many conferences.
Julie has been interviewed and quoted by the Pharmacoeconomics Prix Galien supplement, has been a member of the DIA’s Canadian & North American Programme Steering Committee and has contributed to the Rotation program at Sandoz (clinical, scientific affairs and marketing departments).
La Presse asked her to write a full-page article in the Editorial section regarding drug development costs (April 2002). She has published many publications and posters with the Montréal Economic Institute, Québec Pharmacie, the Journal of Medical Economics, the Drug Information Association (DIA) and others.
Julie has furthermore maintained a close and lasting relationship with the academic community. She has aided doctoral students as thesis pragmatic expert and has been a lecturer for Master’s students at the University of Montreal’s economic department. From 2002-2006, Julie taught health economics at the MBA (MBA 8B1B) level for the group specialized in bio-industries. She has also co-authored a book chapter about health economics of depression (Thérapeutique Psychiatrique, Éd. Hermann, 1995).
Attention regarding the relationship between costs and efficacy of life sciences is relatively recent. The urgent need for health outcomes research was highlighted in the early 80s. Considering the spiraling escalating rise in healthcare costs, the demand for a more rational allocations of life science products and services has never been more crucial. For instance, 4 decades ago, physicians only had to choose among available interventions by referring to clinical endpoints (safety and efficacy); sales representatives would inform physicians on a given product and expect them to prescribe and adopt it.
Whether they like it or not, healthcare professionals must now also examine costs, as governments, hospitalsand private third party payers are striving to optimize care to patients subject to their existing budgets. A product has no longer to be safe and efficacious; it must also be efficient. On the other side, the struggle of generating a positive return on investment for healthcare products and services has neverbeen more challenging.
Since healthcare professionals, payers, policymakersand producers of healthcare technologies are often faced with the difficult task of assessing the value of a new product or justifying the addition of a new clinical service, either costs, effectiveness or market size is often the only factor considered.
No matter how wealthy the economy of a nation is and how strong its economic system is, there will never be unlimited resources to satisfy the society’s needs. Policymakers, consumers, producers of healthcare technologies, payers and all other individuals and groups involved in the economy must make hard choices about how to allocate resources.
When individuals choose to purchase a medication, they cannot use the same money to purchase something else. Similarly, when governmental policymakers authorize expenditures on medications, there are competing demands that cannot be fulfilled. This idea can be generalized into one of the most important concepts guiding economics: the opportunity cost. Economics, whether applied to life sciences or to any other goods and services, is not about reducing costs (cost containment strategies), it is about maximizing their net outcomes subject to society’s given available resources.
Most of the actual interventions seek to control costs rather than to improve the efficiency of resource allocation. Sound economic studies seek to improve the methodological issues and principles of clinico-economic evaluations.
Finally, it is not important for healthcare actors to be able to perform health economic studies but it is essential for them to understand how and why these analyses are performed and thus, why certain recommendations were outlined. Health care actors should remember that the national Health Care system is seeking to deliver the most efficient healthcare, not the cheapest one.
Spending is not the enemy – wasting is!
Data 4 Actions is a company specialized in behavioral health economics. Our strength is that we master microeconomic notions that can translate into a powerful research protocol that will have the ability to influence end-users about the economic relevance of a given product or service.
At Data 4 Actions, we go beyond writing a report with rigorous and sound data. We strive to transform data into a meaningful story that informs the 5Ps of the economic relevance ofa given product or service and thus, justify the need to take action.
At Data 4 Actions, because of our background,we apply underlying behavioral microeconomics notions to our projects. This enables topromote powerful and meaningful reports that will leverage actionable strategies that will influence healthcare actors - 5Ps -; rather than opting for strategies dealing primarily with cost-containment that will ultimately lead to wastage.
How do we build each customized stories? We build them, over and above our experience, expertise and dedication to success for each of the 5Ps, through:
Julie loves to share her passion and experience about health economics. Hence, she was invited to be a spokesperson in many events. These events mostly consist of:
Health Canada : Health Economic Training
Strategic Pricing Symposium (Montreal)
Oswestry Cartilage Meeting (Oswestry, UK)
Montreal Economic Institute (Montréal)
Université Laval – Presentation to the infectious disorder department (Québec)
Drug Information Association (San Diego, USA)
Wound Care Congress (Montreal)
World Vaccine (Montreal)
Annual symposium - Association des hôpitaux du Québec (Montreal)
Les médicaments en l’an 2000, Virage 98 (Montreal)
BioAlliance Canada-Maroc (Montreal)
UQAM (lecturer) – MBA department
UQAM - Guest speaker
Université Laval – Guest speaker
Université de Montréal – Guest speaker
Over the last 25 years, Julie built “health economic stories”. Please find hereunder a list of the impact of some of her projects.
Through the economic strategies that were designed in collaboration with the client, many products were listed for reimbursement; even for products that were highly challenging due to their significant premium price to competition.
Collaborated to the economic strategy and implantation of international clinical trials, implicating up to 7 countries; for phase I to phase IV trials, secondary or primary to a clinical trial strategy/design.
Through various complementary rigorous economic assesments, managed to influence a top 5 worldwide pharmaceutical to adapt an independent Canadian strategy (significant price reduction of the medication)
100% of the projects that were submited were approved by the ethics committees (hospital/private)
Through the results of Willingness-to-pay trials results generated significant impact on the redesign of the strategic business plan
Collaborated with many small biopharma’s to assess the economic market risk/value of their various indications; frequent collaboration to assist them in the complex task of go/no analyses through economic data.
Collaborated to strategies and implementation of large multi-center trials; implicating more than 3000 patients and 500 physicians.
Project leader for l’Institut Économique de Montréal to determine the feasibility and success factors for enabling nurses and specialized physicians to offer their services in the private sector, over and above their actual scope in the public sector.
Collaborated with venture capital firms to assess the economic risks of investing healthcare technology firms (go/no go).
Collaborated with healthcare technology firms to strengthen their business plan (through economic data) to optimize investment funds from venture capital firms and pharmaceuticals.
Over the last 25 years, Julie has performed projects in various indications and adapting various methodologies. Please find hereunder a list of her various experience over the last 25 years.
Chronic disorders prevention
Chronic heart failure
GBS for intrapartum maternity patients
gestational diabetes mellitus
Hand hygiene program
Medication distribution system
Myocardial infarction prevention
Prevention of C-sections
Upper body disablement
Urinary tract infections
Virtual surgery simulation
Burden of illness study
disease management program
Economic clinico-economic model
Economic piggyback trial
Economic Risk management trial
Patient management program
Time and motion study
Willingness to pay